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Abstract Like the apolipoprotein E (APOE) gene, the most
common genetic determinant for Alzheimer’s disease (AD),
the cholesteryl ester transfer protein (CETP) is involved in
lipid metabolism. We studied the I405V polymorphism of the
CETP gene in relation to AD. We genotyped 544 AD cases
and 5,404 controls from the Rotterdam study, using a TaqMan
allelic discrimination assay. Odds ratios (ORs) for AD were
estimated using logistic regression analysis. CETP VV
carriers showed significantly increased high-density lipopro-
tein levels compared to the IV and II carriers. In the overall
analysis of AD, the risk of disease for the VV carriers of the
CETP polymorphism was non-significantly increased com-
pared to II carriers ORVV=1.33, 95% confidence interval (CI)
0.96–1.90 p=0.08). In those without the APOE*4 allele, the
risk of AD for VV carriers was increased 1.67-fold (95% CI
1.11–2.52, p=0.01). The difference in the relationship
between CETP and AD between APOE*4 carriers and
APOE*4 non-carriers was statistically significant (p for
interaction=0.04). Our results suggest that the VV genotype
of the I405V polymorphism of the CETP gene increases the
risk of AD in the absence of the APOE*4 allele, probably
through a cholesterol metabolism pathway in the brain.
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Introduction
Alzheimer’s disease (AD) is a complex neurodegenerative
disorder characterized by progressive memory loss and
deterioration of cognitive function. Of the many genes
studied thus far, the only consistently replicated genetic risk
factor for AD has been the apolipoprotein E (APOE) gene.
APOE, which transports cholesterol in the brain [1], may
relate to AD by modifying the production of Amyloid β
(Aβ). High cellular cholesterol may promote Aβ produc-
tion and senile plaque deposition, thus increasing the risk of
AD [2–7]. Cholesterol dysregulation is linked to the
pathogenesis of AD [8, 9]. Lack of cholesterol supply to
neurons impairs neurotransmission and synaptic plasticity
[10] and induces neurodegeneration and tau pathology [11].
Additionally, there is some evidence that patients treated
with cholesterol lowering drugs, such as statins, have a
reduced prevalence of AD [12].
High-density lipoprotein (HDL), essential for the removal
of excess cholesterol from cells, exerts several potentially anti-
atherogenic effects, including reverse cholesterol transport
from peripheral cells to the liver [13]. Cholesteryl ester transfer
protein (CETP) is a key player in lipid metabolism that
catalyses the transfer of cholesteryl esters from HDL particles
to triglyceride-rich lipoproteins in exchange for triglycerides
[14]. CETP, a protein composed of 439 amino acid residues,
is coded by the CETP gene, which is located on chromosome
16q21 and contains 14 exons. The 405V allele of the CETP
Neurogenetics (2007) 8:189–193
DOI 10.1007/s10048-007-0089-x
A. Arias-Vásquez :A. Isaacs :Y. S. Aulchenko :A. Hofman :
M. Breteler : C. M. van Duijn
Department of Epidemiology & Biostatistics,
Erasmus Medical Center Rotterdam,
Rotterdam, The Netherlands
B. A. Oostra
Department of Clinical Genetics,




Department of Epidemiology & Biostatistics,
Erasmus Medical Center Rotterdam,
P.O. Box 2040, 3000 CA Rotterdam, The Netherlands
e-mail: a.ariasvasquez@erasmusmc.nl
I405V polymorphism (rs5882) in exon 14 was previously
associated with lower levels of CETP protein, higher levels of
circulating HDL [15], a lower incidence of cardiovascular
disease [15], and longer survival [16].
Studies evaluating the role of the CETP gene in AD have
shown intriguing results. While one previous study [17]
showed evidence that the C-629A polymorphism of the
CETP gene modifies the risk of AD in association with the
APOE gene by reducing the risk of AD, another study found
no effect of this gene on the disease [18]. We studied the
I405V polymorphism of the CETP gene in relation to AD in a
large population-based study and investigated whether this
polymorphism is independently associated with AD, or acts in
concert with the APOE gene in conferring risk for the disease.
Materials and methods
Study population
Our study is part of the Rotterdam study, a population-
based follow-up study of determinants of diseases in the
elderly. All inhabitants of Ommoord, a suburb of Rotter-
dam, aged 55 years or more, were invited to participate.
The design of the study was previously described [19].
From all subjects, an informed consent was obtained and
the Medical Ethics committee of the Erasmus Medical
Center approved the study. A number of 7,983 participants
(response rate of 78%) were examined at baseline (1990 to
1993). Information on age, smoking behavior, and medical
history was obtained using a computerized questionnaire.
Patient ascertainment
Dementia was diagnosed following a three-step protocol [20,
21]. All participants were screened at follow-up visits using
two tests of cognition: the mini-mental state examination
(MMSE) [22] and the geriatric mental state schedule (GMS)
[23]. Participants that were screen-positives (MMSE
score<26 or GMS organic level>0) underwent the Cambridge
examination for mental disorders of the elderly (CAMDEX).
In addition, the cohort was continuously monitored for
incident dementia through a computerized link between the
study database and the medical records from general prac-
titioners and the Regional Institute for Outpatient Mental
Health Care until January 1, 2005. The diagnosis of dementia,
and dementia subtype, was made in accordance with accepted
criteria for dementia (DSM-III-R) [24] and Alzheimer’s
disease (NINDS-ADRDA) [25] by a panel consisting of a
neurologist, a neuropsychologist and a research physician.
Genotyping
DNAwas extracted from whole blood samples using standard
methods [26]. The APOE gene was genotyped using the
conditions described by Wenham et al. [27]. Samples were
genotyped for the CETP I405V polymorphism using a
TaqMan allelic discrimination Assay-By-Design (Applied
Biosystems, Foster City, CA). We genotyped 317 samples
twice and used them as controls by comparing both
genotypes, and if present, samples with discordant genotypes
were excluded. Forward and reverse primer sequences are
available on request. The assays utilized 5 ng of genomic
DNA and 2 μl reaction volumes. The amplification and
extension protocol was as follows: an initial activation step
of 10 min at 95°C preceded 40 cycles of denaturation at 95°C
for 15 s. and annealing and extension at 50°C for 60 s.
Allele-specific fluorescence was then analyzed on an ABI
Prism 7900HT Sequence Detection System with SDS v 2.1
(Applied Biosystems, Foster City, CA).
Statistical analysis
Genotype frequency of the CETP I405V was compared
between cases and controls and Hardy-Weinberg equilibri-
um (HWE) was assessed for all genotypes using the χ2 test.
Odds ratios (OR) and 95% confidence intervals (CI) were
estimated using multivariate logistic regression, adjusting
for age, gender, and APOE*4 status, using all available AD
cases (prevalent and incident). The APOE*4 stratified
analyses were adjusted for age and gender. All analyses
were performed using SPSS 11.0
Results
Table 1 shows the general characteristics of the study po-
pulation. The distribution of the CETP I405V genotypes was
Table 1 General characteris-
tics of the study population
stratified by CETP genotype
*p=0.001
Genotype II IV VV
Total typed (%) 2,949 (36.9) 2,826 (35.4) 646 (10.1)
Mean age of entry in years (SD) 69.4 (9.2) 69.5 (9.2) 69.1 (9.0)
Female (%) 1,702 (59.9) 1,608 (59.1) 369 (59.0)
Mean HDL levels mmol/l (SD)* 1.33 (0.37) 1.34 (0.36) 1.39 (0.39)
Mean total cholesterol levels mmol/l (SD) 6.61 (1.21) 6.60 (1.24) 6.61 (1.23)
APOE*4 carriers (%) 790 (29.3) 733 (28.2) 156 (26.8)
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in HWE (p=0.38). The mean serum HDL level of the VV
carriers was significantly increased compared to the IVand II
carriers (p=0.001). There were no statistically significant
differences in the distributions of the other variables between
the genotype groups.
The genotype frequencies of the CETP I405V polymor-
phism are shown in Table 2. Overall, we did not find any
significant difference in the genotypic distribution of the
CETP I405V polymorphism between AD cases (prevalent
and incident) and controls. After stratifying for APOE*4,
we found a statistically significant difference in the
distribution between cases and controls in those without
APOE*4 (χ2=6.62, p=0.04). This difference was explained
by an increased frequency of the VV genotype in cases.
Table 3 shows the odds ratios overall and stratified by
APOE*4. Including all prevalent and incident cases, a non-
significant increase in the odds ratios was seen in the
overall analysis when comparing the VV carriers to the II
carriers of the I405V polymorphism, (OR=1.33, 95% CI
0.96–1.90, p=0.08). In those without APOE*4, the OR
increased to 1.67 (95% CI 1.11–2.52, p=0.01). The IV
carriers showed a non-significant increase in risk of AD
compared to II carriers in those without APOE*4, OR=
1.26 (95% CI 0.96–1.64, p=0.09). These estimates did not
change after adjusting for serum HDL levels. Serum HDL
level itself was not associated with AD. The frequencies of
the CETP genotypes in the two types of cases (incident and
prevalent) were not statistically different. This indicates that
the AD patient selection does not affect the proposed
genotype-outcome relationship. When we restricted the
analysis to the incident cases only, the OR for the VV
carriers compared to the II carriers was 1.24 (0.86–1.82,
p=0.24) in the overall analysis. This OR significantly
increased to 1.58 (1.0–2.5, p=0.05). When we analyzed the
incident and prevalent cases together we did not detect an
effect of the VV genotype of the CETP gene on the risk of
AD in those with APOE*4 (p=0.65; Table 3). The
difference in the relationship of the CETP gene and AD
between APOE*4 carriers and non-carriers was statistically
significant (p for interaction=0.04). The mean age at onset
in patients carrying the VV genotype of the CETP I405V
polymorphism (88.64 years, SD=7.19) did not differ
significantly compared to that of the II and IV carriers
(88.75 years, SD=8.02 for IV carriers and 87.75 years,
SD=817 for II carriers, p=0.41). In those without the
APOE*4 allele, the difference in age at onset between VV
carriers and non-carriers was also not significant (p=0.48).
Discussion
Our results suggest an increased risk of AD for carriers of
the VV genotype of the I405V polymorphism in the CETP
gene. The increase in risk was 1.67-fold in non-carriers of
the APOE*4 allele. No association was observed between
this CETP polymorphism and AD in those with the
APOE*4 allele. We detected a statistically significant
difference in the relationship between CETP and AD in
APOE*4 carriers and non-carriers (p for interaction=0.04).
The association was independent of serum HDL levels,
which by itself was not associated with AD.
The relationship between lipid transfer proteins, such as
CETP, and AD has been previously studied. In an
experimental study, Yamada et al. [28] showed that in
brains of patients with AD, reactive astrocytes in gray and
white matter exhibit CETP-like immunoreactivity. Thus,
CETP-positive astrocytes may play a role in the pathology
of Alzheimer’s disease, in particular tissue repair. Our
findings partly overlap with those of other genetic studies.
The CETP C-629A and TaqI B polymorphisms have been
studied with respect to AD. A study in a Spanish population
of the relationship between the CETP C-629A and I405V
polymorphisms and the APOE*4 allele indicated that the
CETP gene modifies AD risk possibly through modulation
of brain cholesterol metabolism [17]. This modification
effect was seen only for the C-629A polymorphism and not
for the I405V. This could be explained by the LD pattern of
Table 3 Association analyses between CETP I405V polymorphism
and ADa in the Rotterdam study
OR IV (95% CI) OR VV (95% CI)
Overall b 1.11 (0.91–1.36) 1.33 (0.96–1.90)
APOE*4+c 0.91 (0.66–1.26) 0.91 (0.51–1.60)
APOE*4−c 1.26 (0.96–1.64) 1.67 (1.11–2.52)
a Incident and prevalent cases included
bModels adjusted for age, sex, and APOE*4
cModel adjusted for age and sex
Table 2 Distribution of the
CETP I405V polymorphism in
cases and controls overall
and by APOE*4
*p=0.04
Genotype Overall APOE*4+ APOE*4−
Cases (%) Controls (%) Cases (%) Controls (%) Cases (%) Controls (%)
II 236 (43.4) 2604 (46.1) 106 (49.8) 684 (46.7) 121 (38.8) 1,806 (45.9)
IV 249 (45.8) 2474 (43.8) 89 (41.8) 644 (43.9) 151 (48.4) 1,738 (44.1)
VV 59 (10.8) 566 (10.0) 18 (8.5) 138 (9.4) *40 (12.8) 394 (10.0)
Total 544 5644 213 1466 312 3938
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these two polymorphisms, but according to data available
in HapMap [29], the D′ and r2 values between these two
variants are not high enough that can serve as tagging
markers for each other in this gene (D′=0.51, r2=0.076).
On the other hand, studies that evaluated the effect of other
promoter polymorphisms and the TaqI B polymorphism
found no effect of this gene on the disease [18, 30].
Since the VV genotype is associated with lower levels of
CETP and higher HDL, our study is compatible with the view
that low CETP levels may increase the risk of AD through a
reduction in neuronal repair capacity. An alternative mecha-
nism is related to cholesterol removal by HDL; this is one of
the mechanisms that cells use to keep the levels of cholesterol
in their membranes fairly constant [9, 13, 31]. This would
imply that VV carriers might be at lower risk of developing
AD. The fact that we found this group to be at a higher risk
of AD could be explained by previous findings suggesting
that the actions of HDL in the transfer of lipids in brain may
differ from those in the peripheral system [32]. In fact, the
processing of cholesterol in brain is restricted in the central
nervous system by the blood-brain barrier, which is
impermeable to plasma lipoproteins [33]. Unlike fatty acids
that must be transported to the central nervous system from
the periphery, brain cholesterol is mainly independent of
dietary uptake or synthesis in the liver and is synthesized
almost entirely in the brain [34]. The CETP and APOE genes
overlap physiologically [35, 36], which provides extra
support for a role of the CETP gene independent of the
APOE gene in the risk of Alzheimer’s disease. In our overall
analysis (all cases and controls, all APOE*4 carriers), we
observed a borderline significant association between the VV
carriers and AD of 1.33, (95% CI 0.96–1.90 p=0.08), which
could indicate that the effect of the CETP gene is observable
in both APOE*4 groups, but after stratification by APOE*4,
in the carrier group, the effect of the CETP gene is
overwhelmed by APOE.
Taken together, our results suggest that the V allele of the
I405V polymorphism of the CETP gene increases the risk of
AD independently of the APOE gene, probably through the
regulation of cholesterol metabolism in the brain. Our data,
however, are not supported by the literature, which calls for
more studies needed to clarify the role of the CETP gene, as
well as the CETP protein and HDL cholesterol, in AD.
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